- Home
- EEA vs ITRM Comparison
EEA vs ITRM Comparison
Compare EEA & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- ITRM
- Stock Information
- Founded
- EEA 1986
- ITRM 2015
- Country
- EEA Germany
- ITRM Ireland
- Employees
- EEA N/A
- ITRM N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- ITRM Health Care
- Exchange
- EEA Nasdaq
- ITRM Nasdaq
- Market Cap
- EEA 57.7M
- ITRM 49.5M
- IPO Year
- EEA N/A
- ITRM 2018
- Fundamental
- Price
- EEA $8.99
- ITRM $1.49
- Analyst Decision
- EEA
- ITRM Strong Buy
- Analyst Count
- EEA 0
- ITRM 1
- Target Price
- EEA N/A
- ITRM $5.00
- AVG Volume (30 Days)
- EEA 9.2K
- ITRM 635.0K
- Earning Date
- EEA 01-01-0001
- ITRM 02-07-2025
- Dividend Yield
- EEA 1.92%
- ITRM N/A
- EPS Growth
- EEA N/A
- ITRM N/A
- EPS
- EEA N/A
- ITRM N/A
- Revenue
- EEA N/A
- ITRM N/A
- Revenue This Year
- EEA N/A
- ITRM N/A
- Revenue Next Year
- EEA N/A
- ITRM $160.88
- P/E Ratio
- EEA N/A
- ITRM N/A
- Revenue Growth
- EEA N/A
- ITRM N/A
- 52 Week Low
- EEA $7.45
- ITRM $0.81
- 52 Week High
- EEA $9.26
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- EEA 64.38
- ITRM 46.16
- Support Level
- EEA $8.97
- ITRM $1.42
- Resistance Level
- EEA $9.15
- ITRM $1.58
- Average True Range (ATR)
- EEA 0.11
- ITRM 0.11
- MACD
- EEA 0.02
- ITRM 0.02
- Stochastic Oscillator
- EEA 71.93
- ITRM 61.76
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.